Archives: Speakers

With over 35 years of clinical research experience, Peter brings medical, scientific, and business insights into oncology and hematology drug development. His understanding of the clinical development – ranging from feasibility assessments, medical monitoring oversight, regulatory strategy, and patient safety provide him with insights for our conversation on how emerging immunotherapy combinations and novel approaches are influencing global clinical research.

Peter holds an MD and PhD from Ludwig-Maximilians-Universität München.

Adam Callahan is VP Global Therapeutic Area Head, Oncology & Hematology at Caidya. Adam brings nearly 30 years of experience and a strong record of building high-performing, global teams that drive clinical programs for regulatory approval and commercialization of therapies. Adam leads a team of medical, scientific, and clinical development experts who engage early and often to help refine sponsor strategies, improve targeting, and accelerate delivery.

Adam’s teams also bring an adeptness in molecule-to-market strategies and operational excellence. Adam’s operational acumen ensures Caidya’s ability to provide development strategies while delivering exceptional experiences for our clients.

Tariq is a Lead Clinic Trial Liaison at Regeneron responsible for expanding the clinical trial footprint in the region, providing key scientific insights and overseeing the successful delivery of oncology trials. With over 15 years of Oncology research experience, his leadership and strategic insight have fostered strong collaborations with the NHS, Private Hospitals, and research bodies such as the NIHR and Cancer Trials Office (Ireland).  These partnerships have driven impactful initiatives, with a view to significantly advancing oncology clinical research across UK and Ireland.

Dr. Marina Murphy is Senior Director of Scientific Affairs at Haypp Group, where she leads scientific communications and public health advocacy to support tobacco harm reduction. With over 20 years’ experience, she has held senior roles at Juul Labs, British American Tobacco, and ANDS, focusing on translating complex science into accessible, evidence-based narratives. Marina is a passionate advocate for transparent science communication and sound regulatory frameworks that support public health. A vocal proponent of evidence-based policy, she regularly addresses misinformation around nicotine products.

Marina holds a Ph.D. in chemistry from the National University of Ireland, Galway and a Masters in Science Communication for Dublin City University, Ireland.